Structured Peer-delivered ART and Reentry Community Strategy (SPARCS) to overcome barriers to HIV care continuity during community reentry from incarceration in South Africa
结构化的同伴提供的 ART 和重返社区策略 (SPARCS),以克服南非监狱出狱重返社区期间艾滋病毒护理连续性的障碍
基本信息
- 批准号:10700511
- 负责人:
- 金额:$ 62.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjusted Life YearsAdoptedAdoptionAdultAgeBehavioralCaringCause of DeathClinicCollaborationsCommunitiesContinuity of Patient CareEducational CurriculumEffectivenessElementsEnvironmentEquilibriumFailureFutureGeneral PopulationGoalsGovernmentGroup StructureHIVHealthHealth systemHybridsImprisonmentIndividualInterventionIntervention StudiesInterviewKnowledgeLifeMaintenanceManualsMeasuresMethodsModificationNational Institute of Mental HealthOutcomeOutputParticipantPersonsPilot ProjectsPolicy MakerPopulationPrevalenceProblem SolvingRandomizedRandomized, Controlled TrialsReach, Effectiveness, Adoption, Implementation, and MaintenanceResourcesRoleSamplingScheduleSelf EfficacyServicesSocial supportSouth AfricaSouth AfricanStructureTechniquesTestingTreatment FailureUnited States National Institutes of HealthViral Load resultWorkage groupantiretroviral therapycommunity cliniccommunity reentrycomparative cost effectivenesscostcost comparisoncost effectivenessdesigndisparity reductioneffectiveness evaluationeffectiveness outcomeeffectiveness testingeffectiveness/implementation studyepidemic responsefinancial literacyhigh riskimplementation costimplementation determinantsimplementation fidelityimplementation strategyimprovedimproved outcomeinterestmemberpeerpilot testprimary outcomescale upsexskillssocietal costsstatisticssubstance usetreatment armtreatment as usualtrial designtrial enrollmentusual care arm
项目摘要
PROJECT SUMMARY
HIV remains the leading cause of death among adults in South Africa despite the availability of antiretroviral
therapy (ART) due to failure to initiate ART and failure to remain on ART. Gaps in HIV care are especially
prominent among key populations at high risk for both HIV and reduced use of HIV services. One population
with an HIV prevalence double the age and sex-matched general population (23%) and with low engagement
in HIV care is individuals recently released from incarceration. During incarceration >90% initiate ART;
following reentry into the community only 34% remain in care. The transition from the controlled carceral
environment and its restricted autonomy to life in the community requires reestablishing planning skills, self-
efficacy, and social support and overcoming bureaucratic barriers to accessing community clinics. We have
demonstrated that an intervention that circumvents clinic barriers by directly providing ART and builds
behavioral skills through peer-facilitator led group sessions improves care continuity following release from
incarceration. In a pilot study of this intervention supported by NIMH, termed SPARCS, among 176
participants, 36% of those in the care as usual compared to 61% of those in the intervention arm were in-care
6 months after corrections release. These results raise important questions regarding possibility of
programmatic scale-up. Scale-up requires achieving a balance between effectiveness, feasibility, and cost.
Notably, the tension between effectiveness and feasibility may require reducing overall effectiveness – such as
by eliminating a component of SPARCS – to increase feasibility. To explore each of these questions, we are
proposing a hybrid type I effectiveness-implementation study structed with the RE-AIM framework (Reach,
Effectiveness, Adoption, Implementation, Maintenance). First, we are proposing a 2x2 factorial design to
maximize power of a randomized controlled trial of the Full-SPARCS intervention and the two distinct
components termed “ART-SPARCS” and “Group-SPARCS” and usual care, to test for a difference in viral load
suppression 6 months from correctional facility release. Second, we propose characterize implementation in
terms of reach, adoption or adoption potential, acceptability, and fidelity. Finally, will use findings from the RCT
to inform costing and cost-effectiveness to inform policy makers regarding cost of SPARCS and components
and cost-effectiveness of each component and the full SPARCS to inform implementation cost and potential
long-term sustainability or maintenance. This project has the potential to generate considerable new
knowledge on interventions that can improve care continuity for this population and key findings for potential
scale-up relevant to policy makers. This proposed study has the potential to generate actionable knowledge to
improve outcomes for community reentrants and contribute to overall goals of HIV epidemic control.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER J HOFFMANN其他文献
CHRISTOPHER J HOFFMANN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER J HOFFMANN', 18)}}的其他基金
Characterizing medication-assisted opioid use treatment and HIV care delivery for community re-entrants with HIV and opioid use disorder in South Africa
南非艾滋病毒和阿片类药物使用障碍社区重新进入者的药物辅助阿片类药物使用治疗和艾滋病毒护理服务的特点
- 批准号:
10259752 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Prevent TB: Application of choice architecture to implement TB preventive therapy in South Africa
预防结核病:应用选择架构在南非实施结核病预防治疗
- 批准号:
10115605 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Prevent TB: Application of choice architecture to implement TB preventive therapy in South Africa
预防结核病:应用选择架构在南非实施结核病预防治疗
- 批准号:
9927031 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Prevent TB: Application of choice architecture to implement TB preventive therapy in South Africa
预防结核病:应用选择架构在南非实施结核病预防治疗
- 批准号:
10597158 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Corrections2Community: Post-release retention in HIV care for ex-inmates in South Africa
Corrections2Community:南非刑满释放人员出狱后继续接受艾滋病毒护理
- 批准号:
9481618 - 财政年份:2017
- 资助金额:
$ 62.85万 - 项目类别:
Continuity of TB and HIV treatment among inmates after release from prison in Sou
苏市囚犯出狱后继续接受结核病和艾滋病毒治疗
- 批准号:
8261796 - 财政年份:2012
- 资助金额:
$ 62.85万 - 项目类别:
GH11-005, S. Africa: Continuity of TB and HIV treatment among inmates after release from prison in Sou
GH11-005,南非:苏监狱释放后囚犯继续接受结核病和艾滋病毒治疗
- 批准号:
8491775 - 财政年份:2012
- 资助金额:
$ 62.85万 - 项目类别:
CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICA
非洲长期 HAART 期间死亡的原因及其相关性
- 批准号:
8308292 - 财政年份:2010
- 资助金额:
$ 62.85万 - 项目类别:
CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICA
非洲长期 HAART 期间死亡的原因及其相关性
- 批准号:
8479308 - 财政年份:2010
- 资助金额:
$ 62.85万 - 项目类别:
CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICA
非洲长期 HAART 期间死亡的原因及其相关性
- 批准号:
7840699 - 财政年份:2010
- 资助金额:
$ 62.85万 - 项目类别:
相似海外基金
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
- 批准号:
10292270 - 财政年份:2021
- 资助金额:
$ 62.85万 - 项目类别:
Estimation of Quality-Adjusted Life Years via Joint Longitudinal-Survival Modelling
通过联合纵向生存模型估计质量调整生命年
- 批准号:
2203100 - 财政年份:2019
- 资助金额:
$ 62.85万 - 项目类别:
Studentship
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
- 批准号:
9886161 - 财政年份:2018
- 资助金额:
$ 62.85万 - 项目类别:
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
- 批准号:
10372989 - 财政年份:2018
- 资助金额:
$ 62.85万 - 项目类别:
Quality of life and Qualtiy-Adjusted Life Years in breast cancer patients receiving postoperative adjuvant chemotherapy
接受术后辅助化疗的乳腺癌患者的生活质量和质量调整生命年
- 批准号:
24701038 - 财政年份:2012
- 资助金额:
$ 62.85万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Measuring quality adjusted life years in children with autism spectrum disorders
测量自闭症谱系障碍儿童的质量调整生命年
- 批准号:
8061015 - 财政年份:2010
- 资助金额:
$ 62.85万 - 项目类别:
Measuring quality adjusted life years in children with autism spectrum disorders
测量自闭症谱系障碍儿童的质量调整生命年
- 批准号:
7937946 - 财政年份:2009
- 资助金额:
$ 62.85万 - 项目类别:
Measuring quality adjusted life years in children with autism spectrum disorders
测量自闭症谱系障碍儿童的质量调整生命年
- 批准号:
7844242 - 财政年份:2009
- 资助金额:
$ 62.85万 - 项目类别:
NIAAA-07-06 - Disability-adjusted Life Years
NIAAA-07-06 - 伤残调整生命年
- 批准号:
7544017 - 财政年份:2007
- 资助金额:
$ 62.85万 - 项目类别:














{{item.name}}会员




